Click a keyword to view all the abstracts on this site tagged with that keyword.
- anti-citrullinated protein/peptide antibodies (ACPA) and therapeutic targeting
- anti-cN1A antibodies
- Anti-depressant
- Anti-DNA
- anti-DNA and antibodies
- anti-DNA and lupus nephritis
- Anti-drug antibodies
- anti-drug antibodies and anti-TNF therapy
- anti-dsDNA
- anti-dsDNA and anti-Smith
- anti-dsDNA and cytokines
- anti-dsDNA and glomerulonephritis
- anti-dsDNA and immunoglobulin (IG)
- anti-dsDNA and nephritis
- anti-dsDNA and neuropsychiatric disorders
- anti-dsDNA and Reproductive Health
- Anti-GBM Disease (Goodpasture's)
- Anti-histone antibodies
- Anti-La
- anti-mitochondria antibody
- anti-mitochondria antibody and calcinosis
- anti-mitochondria antibody and prognostic factors
- Anti-MPP1
- anti-mutated citrullinated vimentin
- anti-phosphatidylserine/prothrombin antibodies
- Anti-resorptives
- anti-ribosomal P
- anti-RNA antibodies
- Anti-Ro
- Anti-Synthetase Syndrome and malignancy
- Anti-TNF Drugs
- anti-TNF therapy
- anti-TNF therapy and arthritis
- anti-TNF therapy and axial spondyloarthritis
- anti-TNF therapy and biologic drugs
- anti-TNF therapy and biomarkers
- anti-TNF therapy and biosimilars
- anti-TNF therapy and bone metabolism
- Anti-TNF therapy and cancer
- Anti-TNF therapy and certolizumab pegol
- anti-TNF therapy and clinical practice
- anti-TNF therapy and Clinical Response
- anti-TNF therapy and cytokines
- anti-TNF therapy and Disease Activity
- anti-TNF therapy and drug safety
- anti-TNF therapy and dry eyes
- anti-TNF therapy and epidemiologic methods
- anti-TNF therapy and extraarticular manifestations
- anti-TNF therapy and eye disease
- anti-TNF therapy and Femur Fractures
- Anti-TNF therapy and fractures
- anti-TNF therapy and functional status
- anti-TNF therapy and Golimumab
- Anti-TNF therapy and health care cost
- anti-TNF therapy and Immunotherapy
- Anti-TNF therapy and infection
- anti-TNF therapy and inflammation
- anti-TNF therapy and infliximab
- Anti-TNF therapy and juvenile idiopathic arthritis (JIA)
- anti-TNF therapy and magnetic resonance imaging (MRI)
- anti-TNF therapy and methotrexate (MTX)
- Anti-TNF therapy and monocytes
- anti-TNF therapy and neurologic involvement
- Anti-TNF therapy and pediatric rheumatology
- anti-TNF therapy and positron emission tomography (PET)
- anti-TNF therapy and prognostic factors
- anti-TNF therapy and psoriasis
- Anti-TNF therapy and psoriatic arthritis
- anti-TNF therapy and quality of life
- anti-TNF therapy and radiography
- anti-TNF therapy and randomized trials
- anti-TNF therapy and registries
- anti-TNF therapy and registry
- anti-TNF therapy and remission
- anti-TNF therapy and rheumatic disease
- Anti-TNF therapy and rheumatoid arthritis
- Anti-TNF therapy and rheumatoid arthritis (RA)
- Anti-TNF therapy and rituximab
- anti-TNF therapy and safety
- anti-TNF therapy and spine involvement
- Anti-TNF therapy and spondylarthritis
- Anti-TNF therapy and spondylarthropathy
- anti-TNF therapy and taper
- anti-TNF therapy and tnf
- anti-TNF therapy and tocilizumab
- anti-TNF therapy and tolerance
- Anti-TNF therapy and treatment
- Anti-TNF therapy and tuberculosis
- anti-TNF therapy and tumor necrosis factor (TNF)
- anti-TNF therapy and uveitis
- anti-TNF therapy and vaccines
- Anti-TNF therapy and vasculitis
- anti-β2-glycoprotein I Domain1 and IgA isotype
- antiangiogenetic chemokines and IL-33
- antibiotic therapy
- Antibiotics
- antibiotics and dermatomyositis
- antibiotics and Electronic Health Record
- Antibodies
- antibodies and arthritis
- antibodies and autoantibodies
- Antibodies and autoimmune diseases
- antibodies and big data
- Antibodies and biomarkers
- antibodies and citrullination
- antibodies and diagnosis
- antibodies and Diagnostic Tests
- antibodies and flow cytometry
- antibodies and inflammatory arthritis
- antibodies and interleukins (IL)
- antibodies and juvenile idiopathic arthritis-enthesitis (ERA)
- Antibodies and myositis
- antibodies and pediatric rheumatology
- antibodies and pediatrics
- antibodies and pregnancy
- antibodies and rheumatic disease
- antibodies and rheumatoid arthritis (RA)
- antibodies and scleroderma
- antibodies and scleroderma-like conditions
- antibodies and spondylarthropathy
- antibodies and statin-induced myopathies
- antibodies and synovial cells
- antibodies and systemic lupus erythematosus (SLE)
- antibodies and systemic sclerosis
- Antibodies and tocilizumab
- antibodies and tofacitinib
- antibodies and tolerance
- antibodies and tumor necrosis factor (TNF)
- antibodies and vaccines
- antibodies and vasculitis
- antibody
- Antibody microarray
- antibody microarray and biomarkers
- Anticardiolipin
- anticardiolipin and systemic lupus erythematosus (SLE)
- Anticoagulation
- Anticoagulation and antiphospholipid
- Anticoagulation and antiphospholipid syndrome
- Anticoagulation and systemic lupus erythematosus (SLE)
- anticoagulation and vasculitis
- antigen and human leukocyte antigens (HLA)
- Antigen Bead Array and Enzyme-Linked Immunoabsorbant Assays (ELISA)
- antigen RA
- antigen RA and rheumatoid arthritis (RA)
- antigen specific Th17 cells and enzyme-linked immunospot assay (ELISPOT)
- antigen-presenting cells
- antigen-presenting cells and axial spondyloarthritis
- antigen-presenting cells and myositis
- antigen-presenting cells and rheumatoid arthritis (RA)
- antigen-presenting cells and tolerance
- Antigens
- antigens and autoantigens
- antigens and biomarkers
- antigens and genomics
- antigens and vasculitis
- antiinflammatory
- Antimalarial drugs
- antimalarial drugs and cardiomyopathy
- antimalarial drugs and drug toxicity
- Antimalarial drugs and systemic lupus erythematosus (SLE)
- antimalarial drugs and treatment
- Antinuclear antibodies (ANA)
- Antinuclear antibodies (ANA) and autoantibodies
- antinuclear antibodies (ANA) and biomarkers
- Antinuclear antibodies (ANA) and health care cost
- antinuclear antibodies (ANA) and laboratory tests
- antinuclear antibodies (ANA) and musculoskeletal disorders
- antinuclear antibodies (ANA) and systemic sclerosis
- Antinuclear antibodies (ANA) and thrombosis
- antinuclear antibodies (ANA) and Utility
- antinucleosome antibodies
- Antinucleosome antibodies and autoantibodies
- Antinucleosome antibodies and systemic lupus erythematosus (SLE)
- antioxidant
- antioxidant and MRL-lpr mouse
- Antioxidants
- antioxidants and mouse model
- antioxidants and osteoarthritis
- antioxidants and osteoclastogenesis
- Antiphospholipid
- antiphospholipid and antiphospholipid antibodies
- antiphospholipid and antiphospholipid syndrome
- antiphospholipid and microbiome
- antiphospholipid and monocytes
- Antiphospholipid and thrombosis
- antiphospholipid and vasculitis
- Antiphospholipid antibodies
- antiphospholipid antibodies and antiphospholipid syndrome
- antiphospholipid antibodies and aPL
- antiphospholipid antibodies and biomarkers
- antiphospholipid antibodies and cardiovascular disease
- antiphospholipid antibodies and Cell Signaling
- antiphospholipid antibodies and cerebrovascular disease
- Antiphospholipid Antibodies and giant cell arteritis
- antiphospholipid antibodies and interferons
- Antiphospholipid Antibodies and myocardial involvement
- Antiphospholipid antibodies and pregnancy
- Antiphospholipid antibodies and systemic lupus erythematosus (SLE)
- Antiphospholipid antibodies and systemic sclerosis
- antiphospholipid antibodies and thrombosis